VFA
NVCR icon

Valeo Financial Advisors’s NovoCure NVCR Stock Holding History

Valeo Financial Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-60
Closed -$8K – 1365
2021
Q1 		$8K Sell
60
-45
-43% -$7.12K ﹤0.01% 1426
2020
Q4 		$18K Buy
+105
New +$14.4K ﹤0.01% 1053
2020
Q3 		– Sell
-142
Closed -$8K – 1966
2020
Q2 		$8K Buy
142
+3
+2% +$197 ﹤0.01% 1368
2020
Q1 		$10K Hold
139
– – ﹤0.01% 1104
2019
Q4 		$12K Buy
+139
New +$11.2K ﹤0.01% 1061
2018
Q4 		– Sell
-63
Closed -$2K – 1645
2018
Q3 		$2K Buy
+63
New +$2.51K ﹤0.01% 1489

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Valeo Financial Advisors's NVCR Position: Q2 2021 in Review

Valeo Financial Advisors sold out of NovoCure (NVCR) in Q2 2021, closing a stake of 60 shares — an estimated $8K sold.

Valeo Financial Advisors first reported a position in NVCR in Q3 2018 and held it in 6 quarters. The position peaked at $18K in Q4 2020. 361 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

  • Valeo Financial Advisors reported no remaining NovoCure position as of Q2 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 60 NovoCure shares in Q2 2021, an estimated $8K.
  • Valeo Financial Advisors first reported a position in NovoCure in Q3 2018 and held it in 6 quarters.
  • Valeo Financial Advisors's NovoCure position peaked at $18K in Q4 2020.
  • 361 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.